1. intensive care admission 2. the need for mechanical ventilation 3. patients with previously known organ (kidney, heart and liver) failure \* to be determined as previously known heart failure (ef \<30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance \<30). 4. covid-19 disease with no indication for hospitalization 5. participants in another clinical trial 6. pregnancy or lactation 7. solid organ or stem cell transplantation story 8. patients with collagen tissue disease 9. use of immunosuppressive therapy 10. procalcitonin ≥2 (baseline visit) 11. under 18 years old 12. those who had myocardial infarction in the last 3 months 13. those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. 14. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate 15. presence of malignancy 16. patients with neurological diseases

1. intensive care admission 2. the need for mechanical ventilation 3. patients with previously known organ (kidney, heart and liver) failure \* to be determined as previously known heart failure (ef \<30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance \<30). 4. covid-19 disease with no indication for hospitalization 5. participants in another clinical trial 6. pregnancy or lactation 7. solid organ or stem cell transplantation story 8. patients with collagen tissue disease 9. use of immunosuppressive therapy 10. procalcitonin ≥2 (baseline visit) 11. under 18 years old 12. those who had myocardial infarction in the last 3 months 13. those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. 14. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate 15. presence of malignancy 16. patients with neurological diseases

intensive care admission the need for mechanical ventilation patients with previously known organ (kidney, heart and liver) failure * to be determined as previously known heart failure (ef <30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance <30). covid-19 disease with no indication for hospitalization participants in another clinical trial pregnancy or lactation solid organ or stem cell transplantation story patients with collagen tissue disease use of immunosuppressive therapy procalcitonin ≥2 (baseline visit) under 18 years old those who had myocardial infarction in the last 3 months those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate presence of malignancy patients with neurological diseases

intensive care admission the need for mechanical ventilation patients with previously known organ (kidney, heart and liver) failure * to be determined as previously known heart failure (ef <30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance <30). covid-19 disease with no indication for hospitalization participants in another clinical trial pregnancy or lactation solid organ or stem cell transplantation story patients with collagen tissue disease use of immunosuppressive therapy procalcitonin ≥2 (baseline visit) under 18 years old those who had myocardial infarction in the last 3 months those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate presence of malignancy patients with neurological diseases

1. intensive care admission 2. the need for mechanical ventilation 3. patients with previously known organ (kidney, heart and liver) failure * to be determined as previously known heart failure (ef <30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance <30). 4. covid-19 disease with no indication for hospitalization 5. participants in another clinical trial 6. pregnancy or lactation 7. solid organ or stem cell transplantation story 8. patients with collagen tissue disease 9. use of immunosuppressive therapy 10. procalcitonin ≥2 (baseline visit) 11. under 18 years old 12. those who had myocardial infarction in the last 3 months 13. those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. 14. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate 15. presence of malignancy 16. patients with neurological diseases

1. intensive care admission 2. the need for mechanical ventilation 3. patients with previously known organ (kidney, heart and liver) failure * to be determined as previously known heart failure (ef <30), previously known liver failure (child-pugh c) and previously known renal failure (cr.clerance <30). 4. covid-19 disease with no indication for hospitalization 5. participants in another clinical trial 6. pregnancy or lactation 7. solid organ or stem cell transplantation story 8. patients with collagen tissue disease 9. use of immunosuppressive therapy 10. procalcitonin ≥2 (baseline visit) 11. under 18 years old 12. those who had myocardial infarction in the last 3 months 13. those who do not have the capacity to understand the possible results, scope and nature of the study due to legal insufficiency and / or other reasons. 14. those who, in the opinion of the investigator, cannot continue the treatment protocol regularly or cannot cooperate 15. presence of malignancy 16. patients with neurological diseases